| Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial (NCT04539366) | National Cancer Institute (NCI) | 2022-01-25 |
| Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors (NCT04851119) | Children's Oncology Group | 2021-11-08 |
| Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients With Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma (NCT04751383) | National Cancer Institute (NCI) | 2021-08-31 |
| Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (NCT04901702) | St. Jude Children's Research Hospital | 2021-06-09 |
| Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04320888) | National Cancer Institute (NCI) | 2021-05-03 |
| Trastuzumab Deruxtecan (DS-8201a) for the Treatment of Recurrent or Refractory Osteosarcoma, Wilms Tumor, and Desmoplastic Small Round Cell Tumor (NCT04616560) | National Cancer Institute (NCI) | 2021-03-08 |
| Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (NCT04668300) | M.D. Anderson Cancer Center | 2020-11-26 |
| Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial (NCT04284774) | National Cancer Institute (NCI) | 2020-10-13 |
| Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants With Recurrent or Refractory Osteosarcoma (NCT03598595) | M.D. Anderson Cancer Center | 2019-01-28 |
| Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) (NCT03698994) | National Cancer Institute (NCI) | 2018-11-14 |
| Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial) (NCT03526250) | National Cancer Institute (NCI) | 2018-08-13 |
| LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas (NCT03449108) | M.D. Anderson Cancer Center | 2018-04-27 |
| Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial) (NCT03213652) | National Cancer Institute (NCI) | 2018-04-17 |
| Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors (NCT03320330) | Children's Oncology Group | 2018-01-31 |
| Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) (NCT03213678) | National Cancer Institute (NCI) | 2017-11-28 |
| Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial) (NCT03213665) | National Cancer Institute (NCI) | 2017-11-13 |
| Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) (NCT03233204) | National Cancer Institute (NCI) | 2017-09-14 |
| Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) (NCT03213704) | National Cancer Institute (NCI) | 2017-08-23 |
| Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) (NCT03155620) | National Cancer Institute (NCI) | 2017-07-31 |
| Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors (NCT02867592) | National Cancer Institute (NCI) | 2017-05-18 |
| Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma (NCT02487979) | National Cancer Institute (NCI) | 2016-02-16 |
| Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma (NCT02484443) | National Cancer Institute (NCI) | 2016-02-04 |
| Denosumab in Treating Patients With Recurrent or Refractory Osteosarcoma (NCT02470091) | Children's Oncology Group | 2015-11-21 |
| Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma (NCT02502786) | Memorial Sloan Kettering Cancer Center | 2015-07-01 |
| Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Sarcomas (NCT02304458) | National Cancer Institute (NCI) | 2015-03-30 |
| Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas (NCT02357810) | Northwestern University | 2015-03-21 |
| Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma (NCT02243605) | National Cancer Institute (NCI) | 2014-12-19 |
| Eribulin Mesylate in Treating Patients With Recurrent or Refractory Osteosarcoma (NCT02097238) | National Cancer Institute (NCI) | 2014-08-01 |
| Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT02011126) | Children's Oncology Group | 2014-06-30 |
| Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma (NCT01614795) | National Cancer Institute (NCI) | 2012-06-18 |
| DNA Biomarkers in Tissue Samples From Patients With Osteosarcoma (NCT01190943) | Children's Oncology Group | 2010-08-06 |
| Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma (NCT01154452) | National Cancer Institute (NCI) | 2010-06-01 |
| Biomarker Expression in Tissue Samples From Patients With Bone Sarcomas (NCT01807052) | Children's Oncology Group | 2009-11-01 |
| Temsirolimus and Cixutumumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Soft Tissue Sarcoma or Bone Sarcoma (NCT01016015) | National Cancer Institute (NCI) | 2009-11-01 |
| Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery (NCT01553539) | Wake Forest University Health Sciences | 2009-10-01 |
| Study of Blood Samples From Patients With Osteosarcoma (NCT00954473) | Children's Oncology Group | 2009-01-01 |
| Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors (NCT00831844) | National Cancer Institute (NCI) | 2009-01-01 |
| Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) (NCT00330421) | National Cancer Institute (NCI) | 2006-06-01 |
| Ixabepilone in Treating Young Patients With Refractory Solid Tumors (NCT00331643) | National Cancer Institute (NCI) | 2006-04-01 |
| Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas (NCT00101270) | National Cancer Institute (NCI) | 2005-03-01 |
| Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment (NCT00091182) | National Cancer Institute (NCI) | 2004-10-01 |
| Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid Tumors (NCT00093821) | National Cancer Institute (NCI) | 2004-09-01 |
| Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors (NCT00077454) | National Cancer Institute (NCI) | 2004-02-01 |
| Imatinib Mesylate in Treating Patients With Relapsed or Refractory Solid Tumors of Childhood (NCT00030667) | National Cancer Institute (NCI) | 2002-05-01 |
| Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or Lymphomas (NCT00012181) | National Cancer Institute (NCI) | 2001-04-01 |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma (NCT00004241) | National Cancer Institute (NCI) | 1999-10-01 |
| Irinotecan in Treating Children With Refractory Solid Tumors (NCT00004078) | Children's Oncology Group | 1999-10-01 |
| Single-Patient Expanded Access Protocol - RNA-LP in a Patient With Recurrent Osteosarcoma (NCT07560709) | University of Florida | |